These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 26383529)

  • 21. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
    El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
    Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab's antitumor activity against B-cell malignancy.
    Chen YH; Wang Y; Liao CH; Hsu SC
    Sci Rep; 2021 Jun; 11(1):12398. PubMed ID: 34117317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.
    Alcharakh M; Yun S; Dong Y; Vincelette ND; Daud M; Manzoor S; Riaz IB; Anwer F
    Immunotherapy; 2016 Jul; 8(8):847-52. PubMed ID: 27381683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Zhu M; Kratzer A; Johnson J; Holland C; Brandl C; Singh I; Wolf A; Doshi S
    J Clin Pharmacol; 2018 Feb; 58(2):168-179. PubMed ID: 28922466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting non-Hodgkin lymphoma with blinatumomab.
    Sanders S; Stewart DA
    Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
    Meckler JF; Levis DJ; Vang DP; Tuscano JM
    Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
    Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
    Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addressing Administration Challenges Associated With Blinatumomab Infusions: A Multidisciplinary Approach.
    Szoch S; Boord C; Duffy A; Patzke C
    J Infus Nurs; 2018; 41(4):241-246. PubMed ID: 29958260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
    Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
    Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
    Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
    Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.